Fosun Pharmaceutical (HKG:2196, SHA:600196) said it has filed an arbitration against Shanghai Alis Pharmaceutical Technology following media reports regarding a disputed marketing contract between the parties, according to a Sunday disclosure on the Shanghai Stock Exchange.
The Chinese pharmaceutical company, through subsidiary Jiangsu Fosun Pharmaceutical Sales, filed the case at the Shanghai Arbitration Commission in June, seeking 255.5 million yuan for overdue promotion service fees.
This came after Alis Pharmaceutical prematurely terminated on Nov. 30, 2023 its agreement for Fosun to exclusively market vometinib between May 1, 2022 to December 31, 2026.
Price (HKD): $14.50, Change: $+0.080, Percent Change: +0.55%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。